

# Yun-Fan Sun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2293874/publications.pdf>

Version: 2024-02-01

51  
papers

3,264  
citations

304743

22  
h-index

243625

44  
g-index

52  
all docs

52  
docs citations

52  
times ranked

4441  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6212-6222.	7.0	1,012
2	Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. <i>Cell</i> , 2021, 184, 404-421.e16.	28.9	399
3	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. <i>Hepatology</i> , 2013, 57, 1458-1468.	7.3	331
4	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1151-1173.	2.5	160
5	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 $\beta$ and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	17.0	150
6	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	7.0	112
7	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	7.0	102
8	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform. <i>Clinical Cancer Research</i> , 2014, 20, 4794-4805.	7.0	99
9	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	12.8	90
10	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , 2019, 19, 760.	2.6	78
11	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 573.	6.3	65
12	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2015, 468, 525-532.	2.1	59
13	Circulating CD14 <sup>+</sup> HLA <sup>DR</sup> <sup>low</sup> myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. <i>Hepatology Research</i> , 2017, 47, 1061-1071.	3.4	56
14	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. <i>Oncotarget</i> , 2016, 7, 70654-70668.	1.8	44
15	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	5.1	32
16	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , 2021, 41, 562-573.	3.9	32
17	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	6.3	31
18	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 47121-47135.	1.8	29

#	ARTICLE	IF	CITATIONS
19	An Oxygen-Concentration-Controllable Multiorgan Microfluidic Platform for Studying Hypoxia-Induced Lung Cancer-Liver Metastasis and Screening Drugs. <i>ACS Sensors</i> , 2021, 6, 823-832.	7.8	28
20	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	2.5	27
21	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF- $\kappa$ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	4.0	27
22	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1686-1694.	1.5	25
23	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study. <i>Clinical and Translational Medicine</i> , 2020, 10, e137.	4.0	25
24	Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 34571-34581.	1.8	25
25	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. <i>EBioMedicine</i> , 2020, 62, 103107.	6.1	23
26	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. <i>Cancer Letters</i> , 2015, 366, 112-122.	7.2	21
27	PDXliver: a database of liver cancer patient derived xenograft mouse models. <i>BMC Cancer</i> , 2018, 18, 550.	2.6	20
28	Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis. <i>Journal of Gastroenterology</i> , 2016, 51, 722-732.	5.1	19
29	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	2.4	19
30	Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 582-596.	1.5	17
31	Phosphorylase Kinase $\beta$ Represents a Novel Prognostic Biomarker and Inhibits Malignant Phenotypes of Liver Cancer Cell. <i>International Journal of Biological Sciences</i> , 2019, 15, 2596-2606.	6.4	15
32	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	2.8	14
33	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. <i>Cell Death and Disease</i> , 2020, 11, 895.	6.3	11
34	USP1 Maintains the Survival of Liver Circulating Tumor Cells by Deubiquitinating and Stabilizing TBLR1. <i>Frontiers in Oncology</i> , 2020, 10, 554809.	2.8	11
35	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	3.7	9
36	Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX <sup>®</sup> $\times$ 120 Platform: A prospective study. <i>Molecular Oncology</i> , 2021, 15, 2345-2362.	4.6	9

#	ARTICLE	IF	CITATIONS
37	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. <i>Clinica Chimica Acta</i> , 2020, 511, 67-74.	1.1	8
38	Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). <i>Cancer Research</i> , 2021, 81, 486-486.	0.9	7
39	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6281-6290.	2.0	5
40	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2017, 7, 2465-2477.	1.4	5
41	Freehand Minimally Invasive Pedicle Screw Fixation and Minimally Invasive Decompression for a Thoracic or Lumbar Vertebral Metastatic Tumor From Hepatocellular Carcinoma. <i>Frontiers in Surgery</i> , 2021, 8, 723943.	1.4	4
42	Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells. <i>Cancer Biology and Medicine</i> , 2021, 18, 934-936.	3.0	4
43	scDPN for High-throughput Single-cell CNV Detection to Uncover Clonal Evolution During HCC Recurrence. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 346-357.	6.9	3
44	Abstract 5380: An integrated platform for the clinical detection and molecular profiling of single circulating tumor cells. , 2020, , .		1
45	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 847263.	4.8	1
46	Impact of deviated balance of regulatory and cytotoxic T cells on release and reseeding of circulating tumor cells in hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22133-e22133.	1.6	0
47	The biological characteristics and kinetics of circulating tumor cells in hepatocellular carcinoma undergoing surgical interventions.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22013-e22013.	1.6	0
48	The heterogeneity and clinical relevance of circulating tumor-initiating cells in hepatocellular carcinoma using an integrated immunomagnetic-microfluidic platform.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15132-e15132.	1.6	0
49	Elaborating the Tumor Ecosystem of Primary and Relapsed&nbsp;Hepatocellular Carcinoma by Single-Cell RNA Sequencing. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
50	The heterogeneity of genomic biomarkers for immune checkpoint inhibitor in therapy-naïve primary hepatocellular carcinoma and their metachronous metastases.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15665-e15665.	1.6	0
51	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. <i>American Journal of Cancer Research</i> , 2021, 11, 2044-2061.	1.4	0